U.S. retail investor fund flows into Novo Nordisk surged 32-fold on Friday, as the Danish drugmaker's weaker-than-expected ...

Novo Nordisk, Europe’s largest company by market value, faced a stock market bloodbath on Friday after disappointing results ...

Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently ...

The Ozempic maker's stock tanked after its highly anticipated CagriSema drug trial showed an average of 22.7% weight loss, ...

Results for its new CagriSema drug, while promising, fell below expectations, sending shares of the pharmaceutical giant down ...

Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug ...

Novo Nordisk's new weight-loss drug, CagriSema, missed the company's target in Phase 3 trials, causing a 20.37% drop in ...

But in an increasingly competitive market for weight loss drugs, these are not the only options for people looking to lose ...

As of 11:05 a.m. ET, Novo Nordisk stock is down a disheartening 20.8%, while both Lilly and Viking stocks are up 4.4% apiece.

Hardman Johnston Global Advisors, an investment management company, released its “Hardman Johnston Global Equity” third ...

Novo Nordisk's REDEFINE 1 trial shows CagriSema delivers significant weight loss and a favorable safety profile in obesity ...

New clinical trial data from Novo Nordisk raise questions for the broad landscape of obesity drug development and the way ...